Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease

Дата публикации: 21-07-2026 03:07:36

CAMBRIDGE, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced topline results...

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile	0	16.82	10-08-2026
2	Capricor Therapeutics Provides Update on FDA Advisory Committee Meeting for Deramiocel	0	13.9	30-07-2026
3	Ascelia Pharma Provides Update on the Orviglance NDA	0	11.3	03-07-2026
4	Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)	0	12.6	30-06-2026
5	BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9	0	19.68	27-05-2026
6	Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks	0	17.66	06-07-2026
7	Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility	0	13.33	07-08-2026
8	Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome	0	10.77	18-06-2026
9	Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA	0	13.35	22-06-2026
10	GSK Provides an Update on CALM-1 and CALM-2 Phase III Trials for Camlipixant in Refractory Chronic Cough (RCC)	0	7.48	17-07-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 17.79. Источник: www.drugs.com.